HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Lin, C.-C. Articles by Yeh, L.-T. Search for Related Content PubMed PubMed Citation Articles by Lin, C.-C. Articles by Yeh, L.-T. Social Bookmarking                         What's this?

Pharmacokinetics and Safety of Viramidine, a Prodrug of Ribavirin, in Healthy Volunteers

From Research and Development, Valeant Pharmaceuticals International, Costa Mesa, California.

Ribavirin, part of the current first-line combination therapy for the treatment of chronic hepatitis C, has side effects—in particular, hemolytic anemia—that is frequently dose limiting. Based on animal studies, viramidine, a prodrug of ribavirin, is converted to ribavirin in the liver. Viramidine dosing yielded 50% higher ribavirin levels in the monkey liver but only half in plasma and red blood cells compared to ribavirin dosing. At the same dose, it also had a safer profile than ribavirin in a 28-day toxicity study in monkeys. The current study was carried out to evaluate the safety, tolerability, and pharmacokinetics of viramidine in healthy male volunteers (n = 8-18 on viramidine vs. 2 on placebo at each dose level) after oral dosing of viramidine at 200, 600, and 1200 mg. There were no serious adverse events, and most adverse events were mild. The percentages of treatment-emergent events judged to be possibly related to the study drug were 50% in the 1200-mg group, 26% in the 600-mg group, and none in the 200-mg group. Viramidine was orally absorbed and rapidly converted to ribavirin with a t_max of 1.5 to 3.0 hours for both viramidine and ribavirin in plasma. There was dose proportionality in plasma AUC_{0-168 h} and C_max for viramidine and in plasma AUC_{0-168 h} for ribavirin. Plasma AUC_{0-168 h} for ribavirin was two to four times higher than plasma AUC_{0-168 h} for viramidine, indicating that viramidine is extensively metabolized to ribavirin and is a prodrug of ribavirin in man. Amounts of viramidine and ribavirin excreted in the urine were small (2%-5% of dose), indicating that the main route of elimination for both viramidine and ribavirin is metabolism. Both viramidine and ribavirin were excreted into urine through the mechanism of glomerular filtration. In addition, an evaluation of the effect of a high-fat meal on the pharmacokinetics of viramidine and ribavirin after oral dosing of viramidine at 600 mg was conducted in healthy male volunteers (n = 33-34) in a crossover study design. A high-fat meal increased viramidine plasma AUC_{0-168 h} by 44% and C_max by 20%. It also increased ribavirin plasma AUC_{0-168 h} by 19% and C_max by 43%. The clinical relevance of these increases is unknown.

Key Words: Ribavirin • viramidine • pharmacokinetics • safety • tolerability • chronic hepatitis C

Address for reprints: Dr. Chin-Chung Lin, Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, CA 92626.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Michaelis, R. Michaelis, T. Suhan, H. Schmidt, A. Mohamed, H. W. Doerr, and J. Cinatl Jr. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion FASEB J, January 1, 2007; 21(1): 81 - 87. [Abstract] [Full Text] [PDF]

				C.-c. Lin, C. Xu, N. Zhu, and L.-T. Yeh Absorption, Metabolism, and Excretion of [14C]Viramidine in Humans Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2368 - 2373. [Abstract] [Full Text] [PDF]

				R. G. Gish Treating HCV with ribavirin analogues and ribavirin-like molecules J. Antimicrob. Chemother., January 1, 2006; 57(1): 8 - 13. [Abstract] [Full Text] [PDF]